JP2006504751A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504751A5
JP2006504751A5 JP2004544592A JP2004544592A JP2006504751A5 JP 2006504751 A5 JP2006504751 A5 JP 2006504751A5 JP 2004544592 A JP2004544592 A JP 2004544592A JP 2004544592 A JP2004544592 A JP 2004544592A JP 2006504751 A5 JP2006504751 A5 JP 2006504751A5
Authority
JP
Japan
Prior art keywords
methyl
hydrogen
parathyroid
lower alkyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004544592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504751A (ja
JP4672368B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/004514 external-priority patent/WO2004035050A1/en
Publication of JP2006504751A publication Critical patent/JP2006504751A/ja
Publication of JP2006504751A5 publication Critical patent/JP2006504751A5/ja
Application granted granted Critical
Publication of JP4672368B2 publication Critical patent/JP4672368B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004544592A 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Expired - Fee Related JP4672368B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (3)

Publication Number Publication Date
JP2006504751A JP2006504751A (ja) 2006-02-09
JP2006504751A5 true JP2006504751A5 (cg-RX-API-DMAC10.html) 2006-11-30
JP4672368B2 JP4672368B2 (ja) 2011-04-20

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544592A Expired - Fee Related JP4672368B2 (ja) 2002-10-15 2003-10-13 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用

Country Status (15)

Country Link
US (2) US20060142354A1 (cg-RX-API-DMAC10.html)
EP (1) EP1553938B1 (cg-RX-API-DMAC10.html)
JP (1) JP4672368B2 (cg-RX-API-DMAC10.html)
CN (1) CN1297269C (cg-RX-API-DMAC10.html)
AT (1) ATE350034T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003267751A1 (cg-RX-API-DMAC10.html)
BR (1) BR0315293A (cg-RX-API-DMAC10.html)
CA (1) CA2501717C (cg-RX-API-DMAC10.html)
CY (1) CY1106385T1 (cg-RX-API-DMAC10.html)
DE (1) DE60310975T2 (cg-RX-API-DMAC10.html)
DK (1) DK1553938T3 (cg-RX-API-DMAC10.html)
ES (1) ES2279139T3 (cg-RX-API-DMAC10.html)
PT (1) PT1553938E (cg-RX-API-DMAC10.html)
SI (1) SI1553938T1 (cg-RX-API-DMAC10.html)
WO (1) WO2004035050A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Similar Documents

Publication Publication Date Title
RU2003130058A (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
JP2013501731A5 (cg-RX-API-DMAC10.html)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
JP2010500376A5 (cg-RX-API-DMAC10.html)
RU2000113729A (ru) Гетероциклические соединения для ингибирования секреции желудочной кислоты, способы их получения и их фармацевтические компоозиции
JP2019515884A5 (cg-RX-API-DMAC10.html)
JP2009504763A5 (cg-RX-API-DMAC10.html)
JP2006523216A5 (cg-RX-API-DMAC10.html)
JP2006506443A5 (cg-RX-API-DMAC10.html)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2006507220A5 (cg-RX-API-DMAC10.html)
JP2006514092A5 (cg-RX-API-DMAC10.html)
JP2020532562A5 (cg-RX-API-DMAC10.html)
RU2010123028A (ru) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
ES2405323T3 (es) Tratamiento de melanoma
JP2021502392A5 (cg-RX-API-DMAC10.html)
RU2004131214A (ru) Способы лечения когнитивных расстройств
JP6557253B2 (ja) 抗腫瘍化合物としてのシグマ−2受容体リガンド薬物結合体、その合成法及び使用
JP2012525411A5 (cg-RX-API-DMAC10.html)
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
JP2019531286A5 (cg-RX-API-DMAC10.html)
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
ES2203889T3 (es) Tratamiento de infecciones protozoarias.